Education

Q&A: Developing a Custom e-Questionnaire Data Management Solution for Clinical Trials

July 7, 2022

Q&A Interview with Gilles Scuttenaire, Senior Software Engineer In a presentation at BIO IT World 2022, Cognivia’s Gilles Scuttenaire, senior Software Engineer, discussed our custom, end-to-end data management solution for questionnaire data from clinical trials.  What led Cognivia to develop Unik-me, our customized software for administration of e-questionnaires and management of questionnaire data, and how does

Development of end-to-end data management to improve lead times

May 2, 2022

Technical poster submitted to the BIO-IT World and presented on May 3rd 2022. The implementation of an optimized data management pipeline might require multiple underlying technical solutions that should integrate perfectly one with another. It can be complicated to find its own path among off-the-shelf solutions, internal developments or a mix of both to achieve

Top 3 Risks of Unchecked Placebo Response in Clinical Trials

October 6, 2021

Placebo response is one of the biggest threats to clinical data analysis– especially when left unchecked. In this blog, we review the top three risks trial scientists must address (and how to address them). 

Getting New Pain Drugs to Market: 3 Challenges

September 21, 2021

Each September, pain advocates and specialists raise awareness about issues facing the millions of people living with chronic pain. One of the most pressing? The lack of treatments available to alleviate suffering. In this blog, we look at three top challenges of getting new pain drugs to market—and offer a potential solution.

Where Does Placebo Response in Clinical Trials Come From? 6 Influences

July 23, 2021

Placebo response is a major source of noise in trial data analysis, muddying the results and making it more difficult to detect true treatment effect. We know that it’s a pressing problem for clinical trials that needs solving, but where does it come from in the first place? Patient psychology, expectations and baseline severity of the disease play a significant part of a patient’s placebo responsiveness.